+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


PD-1 and PD-L1 Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997433
  • Report
  • March 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Amgen Inc
  • AstraZeneca plc
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc
  • Merck & Co
  • MORE
The PD-1 and PD-L1 inhibitors market studied was anticipated to grow with a CAGR of nearly 18.5% during the forecast period. The major factor attributing to the growth of the market is a steep rise in the global prevalence of various cancers along with increasing elderly population across the geographical locations, mainly in developed and emerging economies. For instance, according to the World health Organization Report, cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths and lung cancer was identified as the most common cause of death with 1.76 million deaths in 2018. Thus, the rise in the volume of patient pool results in the higher demand for the market fueling the global market growth over the forecast period.

Key Market Trends

The PD-1 Inhibitors Segment is Expected to Hold the Largest Market Share in the PD-1 and PD-L1 Inhibitors Market

The PD-1 inhibitors segment is expected to account for the largest revenue over the forecast period the dominance of the segment can be attributed to the increased volume of research activities, approvals and rise in prescriptions of these drugs such as nivolumab and pembrolizumab. Furthermore, an increased adoption of pembrolizumab (KEYTRUDA), the first PD-1 inhibitor since its approval in 2014 due to its proven efficiency to treat multiple FDA-Approved indications like melanoma, non–small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and others which are highly prevalent globally driving the growth of the segment market. On the other hand, the PD-L1 inhibitor segment is expected to witness the fastest CAGR during the forecast period owing to steep rise in adoption of durvalumab (IMFINZI), avelumab (BAVENCIO) and others in the segment. Also, huge investments by the key players in the development of these products is further fuel the segment propelling the global market revenue over the forecast period.

The PD-1 Inhibitors Segment is Expected to Hold the Largest Market Share in the PD-1 and PD-L1 Inhibitors Market

North America is expected to dominate the overall PD-1 and PD-L1 inhibitors market throughout the forecast period. The dominance is due to growing prevalence of various chronic diseases like diabetes, skin cancer, urothelial carcinomas, lung cancers and presence of huge population of baby boomers during the forecast period in the United States necessitating the efficient treatment. For instance, according to the American Cancer Society Inc estimates for the year 2020, lung cancer is the second most common cancer leading to 135,720 deaths in both men and women. The statistics also report that about 13% of all lung cancers are small cell lung cancer (SCLC) and 84% non-small cell lung cancer (NSCLC) in the Unites States which is expected to continue in the future resulting in higher demand for these products fueling the market in the region. Moreover, the significant share of market revenue in the region can be attributed to presence of major key players and huge investment in the R&D activities to develop new products and generic drugs along with incentives by the government to encourage the innovations to decrease the growing disease burden which is likely to provide more opportunities to the growth of PD-1 and PD-L1 inhibitors market during the forecast period.

Competitive Landscape

The PD-1 and PD-L1 inhibitors market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, research collaboration, while others are investing in clinical trials to extend the treatment of other indications with the existing drugs to address the unmet challenges of the disease burden driving the market share. For instance, in June 2019, Merck received accelerated approval from the USFDA for its pembrolizumab (KEYTRUDA) for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy which is likely to boost the market share during the forecast period. Few of the major players currently dominating the industry in terms of revenue are F. Hoffmann-La Roche AG, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AstraZeneca plc, and Bristol‑MyersSquibbCompany.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Amgen Inc
  • AstraZeneca plc
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc
  • Merck & Co
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Investments in R&D and Clinical Trials by Bio-pharmaceutical Industries
4.2.2 Increased Encouragement Initiatives by the Regulatory Authorities with Favorable Approvals and Special Designations
4.3 Market Restraints
4.3.1 Risk of Complications Associated with the Highly Expensive Oncology Treatment
4.3.2 Challenges in Development with Uncertainity in Regulatory Process and High Costs of Tedious Clinical Trials
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Type of Inhibitors
5.1.1 PD-1 Inhibitors
5.1.2 PD-L1 Inhibitors
5.2 Application
5.2.1 Hodgkin Lymphoma
5.2.2 Kidney Cancer
5.2.3 Melanoma
5.2.4 Non-small Cell Lung Cancer
5.2.5 Others
5.3 End-user
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United states Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 Merck & Co
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Sanofi AG
6.1.5 Amgen Inc
6.1.6 Gilead Sciences Inc
6.1.7 AstraZeneca plc
6.1.8 Novartis AG
6.1.9 Pfizer Inc
6.1.10 Celgene Corporation

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Bristol-Myers Squibb Company
  • Merck & Co
  • F. Hoffmann-La Roche AG
  • Sanofi AG
  • Amgen Inc
  • Gilead Sciences Inc
  • AstraZeneca plc
  • Novartis AG
  • Pfizer Inc
  • Celgene Corporation
Note: Product cover images may vary from those shown